Dr Sam Banister - Psychedelics 2.0 and beyond

Please subscribe, like and comment on our videos to show support for EGA, the free way to say thanks for our special charity 😊🍄🌵
We also invite you to visit our website with many more important resources, upcoming event and you can also join our monthly ethnobotanical newsletter and much more - www.entheogenesis.org/
Dr Sam Banister - Psychedelics 2.0 and beyond
In the past decade, there has been an explosion of research focused on the medicinal chemistry of psychedelics. Dozens of companies around the world are developing entirely new psychedelic medicines for the treatment of serious mental health disorders.
Modern psychedelic drug development utilises the most cutting-edge scientific technologies and is illuminated by insights from psychedelic-receptor interactions obtained at an unprecedented level of detail using cryogenic electron microscopy and molecular modelling.
The presentation will describe the rational development of entirely new classes of psychedelic drugs being employed by leading academic laboratories and private companies and what these new medicines will mean for the most desperate patients.
00:00:00 Introduction
00:01:39 Clinical studies of psychedelic medicines
00:03:51 Phenethylamines, ergolines and tryptamines
00:04:32 Optimising psychedelics for therapy
00:06:39 How psychedelics work in the body
00:07:15 Serotonin (5-HT) receptors
00:09:08 Heart disease and 5-HT2B agonism
00:10:49 Future of psychedelic medicine
00:12:15 Psychedelic drug development
00:16:32 Psychedelic neuroplasticity
00:19:03 Psychedelic head twitch response in mice
00:21:43 Virtual reality, computational chemistry, psychedelic receptor and drug modelling
00:23:20 Q&A
Bio
Dr Sam Bannister is currently CSO of Psylo; a biotech start-up focused on the development of next-generation psychedelic medicines. Sam has been developing new therapeutics in the fields of neuropsychiatry and neurology for more than 15 years at leading academic institutions (Stanford University, University of Sydney, UNSW) and biotech start-ups (Tranquis Therapeutics, NaluBio). Prior to founding Psylo, he was Team Leader in Medicinal Chemistry at The Lambert Initiative for Cannabinoid Therapeutics, and was a postdoc at Stanford University studying cannabinoids, psychedelics, and new psychoactive substances (NPS) before that.
His work on the chemistry and pharmacology of new psychoactive substances (sometimes called "research chemicals") has been covered by major newspapers (New York Times, Sydney Morning Herald) and national radio programs (NPR). Sam is an enthusiastic science communicator, appearing as a guest on numerous science podcasts, and regularly presents at community science events such as Pint of Science, National Science Week, Vivid, and The Science Tent at Splendour in the Grass.
----
About EGA.
Entheogenesis Australis is a charitable educational organisation established in 2004. We provide opportunities for critical thinking and knowledge sharing on ethnobotanical plants, fungi, nature, and sustainability. Through our conferences and workshops, we aim to celebrate the culture, art, politics and community around medicine plants in the hope to better wellbeing for humankind and the planet.
To find out more about what we do, head over to our organisational website, www.entheogenesis.org. Also, head to the conference website for more info - www.gardenstates.org